rs148464224
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 3P and 0B. PM2PP3
The NM_015141.4(GPD1L):c.745G>A(p.Val249Met) variant causes a missense change. The variant allele was found at a frequency of 0.00000186 in 1,613,998 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V249L) has been classified as Uncertain significance.
Frequency
Consequence
NM_015141.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
GPD1L | NM_015141.4 | c.745G>A | p.Val249Met | missense_variant | 6/8 | ENST00000282541.10 | |
GPD1L | XM_006713068.3 | c.604G>A | p.Val202Met | missense_variant | 5/7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
GPD1L | ENST00000282541.10 | c.745G>A | p.Val249Met | missense_variant | 6/8 | 1 | NM_015141.4 | P1 | |
GPD1L | ENST00000474846.5 | n.669G>A | non_coding_transcript_exon_variant | 1/3 | 2 | ||||
GPD1L | ENST00000496151.1 | n.246G>A | non_coding_transcript_exon_variant | 1/3 | 2 | ||||
GPD1L | ENST00000428684.1 | c.*372G>A | 3_prime_UTR_variant, NMD_transcript_variant | 5/6 | 5 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152242Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251226Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135876
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461756Hom.: 0 Cov.: 34 AF XY: 0.00 AC XY: 0AN XY: 727178
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152242Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74382
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 31, 2016 | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: 1 paper in HGMD; Absent from ExAC with good coverage - |
Brugada syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 27, 2020 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has been observed in individual(s) with drug-associated torsades de pointes (PMID: 22584458). ClinVar contains an entry for this variant (Variation ID: 402907). This variant is not present in population databases (ExAC no frequency). This sequence change replaces valine with methionine at codon 249 of the GPD1L protein (p.Val249Met). The valine residue is moderately conserved and there is a small physicochemical difference between valine and methionine. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 21, 2023 | The p.V249M variant (also known as c.745G>A), located in coding exon 6 of the GPD1L gene, results from a G to A substitution at nucleotide position 745. The valine at codon 249 is replaced by methionine, an amino acid with highly similar properties. This variant has been detected in an individual from a cohort with drug-induced long QT syndrome (Ramirez AH et al. Pharmacogenomics J., 2013 Aug;13:325-9). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at